Form DFAN14A PROGENICS PHARMACEUTICAL Filed by: Altiva Management Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

(Rule 14a-101)

 

INFORMATION REQUIRED IN PROXY STATEMENT

 

SCHEDULE 14A INFORMATION

 

Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934

 

(Amendment No. )

 

Filed by the Registrant ☐

 

Filed by a Party other than the Registrant ☒

 

Check the appropriate box:

 

☐

Preliminary Proxy Statement

 

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐

Definitive Proxy Statement

 

☒

Definitive Additional Materials

 

☐

Soliciting Material Under Rule 14a-12

  

PROGENICS PHARMACEUTICALS, INC.

(Name of Registrant as Specified in Its Charter)

VELAN CAPITAL, L.P. ALTIVA MANAGEMENT INC. BALAJI VENKATARAMAN VIRINDER NOHRIA LTE PARTNERS, LLC LTE MANAGEMENT, LLC MELKONIAN CAPITAL MANAGEMENT, LLC RYAN MELKONIAN TERENCE COOKE DEEPAK SARPANGAL

(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

☒

No fee required.

 

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

(1)

Title of each class of securities to which transaction applies:

 

 

(2)

Aggregate number of securities to which transaction applies:

 

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

(4)

Proposed maximum aggregate value of transaction:

 

 

(5)

Total fee paid:

 

 

☐

Fee paid previously with preliminary materials:

  

 

☐          Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

 

(1)

Amount previously paid:

 

 

(2)

Form, Schedule or Registration Statement No.:

 

 

(3)

Filing Party:

 

 

(4)

Date Filed:

 

 

Velan Capital, L.P., together with the other participants named herein (collectively, the “Participating Stockholders”), has filed a definitive proxy statement and accompanying GREEN proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes against the election of certain directors of Progenics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at the Company’s 2019 Annual Meeting of Stockholders (the “Annual Meeting”).

 

Item 1: On July 8, 2019, the Participating Stockholders issued the following press release and mailed a flyer to stockholders, a copy of which is attached hereto as Exhibit 1 and is incorporated herein by reference:

VELAN REMINDS STOCKHOLDERS TO FOLLOW ISS’ RECOMMENDATION BY VOTING “AGAINST” PROGENICS PHARMACEUTICALS DIRECTORS PETER CROWLEY AND MICHAEL KISHBAUCH

 

Agrees with ISS that “Board Level Change is Warranted, With the Ultimate Goal of Enhancing Shareholder Board Oversight”

 

Urges Stockholders to Vote Before Thursday, July 11 Annual Meeting

 

Alpharetta, GA – July 8, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(NASDAQ: PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued a statement urging stockholders to follow the recommendation of Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, by voting AGAINST the election of Progenics directors Peter Crowley and Michael Kishbauch at the Company’s upcoming Annual Meeting of Stockholders scheduled to be held on July 11, 2019 (the “Annual Meeting”).

 

We have heard from numerous stockholders, who like Velan, are unhappy with the Progenics Board of Directors (the “Board”), particularly Peter Crowley and Michael Kishbauch, for overseeing years of stock underperformance, value-destructive behavior, unnecessary and persistent stockholder dilution, and entrenchment-minded tactics, all while collecting hefty paydays with minimal accountability.

 

The time to act is NOW. Velan has published a flyer for Progenics stockholders reminding them that time is short and stockholder action is necessary. Velan’s flyer titled “ISS Agrees: Follow Velan's Lead and Vote AGAINST Crowley & Kishbauch” can be viewed by clicking the following link:

 

https://www.savepgnx.com/api/v1/files/e43dddf5-2478-47dc-3b02-08d6fbdf69f0

 

Stockholders have the opportunity to send a clear message to the Board that the troubling status quo is no longer tenable and that accountability in the boardroom is required. Each vote counts; Velan urges stockholders to vote TODAY.

 

FOLLOW ISS AND VOTE AGAINST MESSRS. CROWLEY AND KISHBAUCH TO ACHIEVE THE CHANGE DESPERATELY NEEDED AT PROGENICS.

 

Note: Permission to use quotations neither sought nor obtained. Emphasis added.

 

Investor contacts:

Deepak Sarpangal

(415) 677-7050

[email protected]

www.savePGNX.com

 

Okapi Partners LLC

Pat McHugh / Jason Alexander

+1 (888) 785-6673

[email protected]

 

 

Item 2: On July 8, 2019, the following material was posted by the Participating Stockholders to www.savePGNX.com:

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Chow Tai Fook Jewellery Group Shines on Global Stage with Paris 100 Sponsorship, Promoting Chinese Craftsmanship to Celebrate 95 Years of Heritage
• Um em cada cinco lares recebia benefício do Bolsa Família em 2023
• Fundo Phoenix compra estatal de energia de São Paulo por R$ 1 bilhão